Vitamin E and Alzheimer’s disease: what do we know so far?

Vitamin E and Alzheimer’s disease: what do we know so far?

Declan Browne, Bernadette McGuinness, Jayne V Woodside, Gareth J McKayCentre for Public Health, Queen’s University Belfast, Belfast, UKAbstract: Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various bio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Browne D, McGuinness B, Woodside JV, McKay GJ
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
vitamin E
Alzheimer’s disease
tocopherols
tocotrienols
antioxidants
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/b9d2e66d8f634e0ea0e5e80bb9ca25fb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b9d2e66d8f634e0ea0e5e80bb9ca25fb
record_format dspace
spelling oai:doaj.org-article:b9d2e66d8f634e0ea0e5e80bb9ca25fb2021-12-02T07:00:50ZVitamin E and Alzheimer’s disease: what do we know so far?1178-1998https://doaj.org/article/b9d2e66d8f634e0ea0e5e80bb9ca25fb2019-07-01T00:00:00Zhttps://www.dovepress.com/vitamin-e-and-alzheimerrsquos-disease-what-do-we-know-so-far-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Declan Browne, Bernadette McGuinness, Jayne V Woodside, Gareth J McKayCentre for Public Health, Queen’s University Belfast, Belfast, UKAbstract: Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflammatory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micronutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restrictions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation.Keywords: vitamin E, Alzheimer’s disease, tocopherols, tocotrienols, antioxidantsBrowne DMcGuinness BWoodside JVMcKay GJDove Medical Pressarticlevitamin EAlzheimer’s diseasetocopherolstocotrienolsantioxidantsGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 14, Pp 1303-1317 (2019)
institution DOAJ
collection DOAJ
language EN
topic vitamin E
Alzheimer’s disease
tocopherols
tocotrienols
antioxidants
Geriatrics
RC952-954.6
spellingShingle vitamin E
Alzheimer’s disease
tocopherols
tocotrienols
antioxidants
Geriatrics
RC952-954.6
Browne D
McGuinness B
Woodside JV
McKay GJ
Vitamin E and Alzheimer’s disease: what do we know so far?
description Declan Browne, Bernadette McGuinness, Jayne V Woodside, Gareth J McKayCentre for Public Health, Queen’s University Belfast, Belfast, UKAbstract: Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflammatory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micronutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restrictions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation.Keywords: vitamin E, Alzheimer’s disease, tocopherols, tocotrienols, antioxidants
format article
author Browne D
McGuinness B
Woodside JV
McKay GJ
author_facet Browne D
McGuinness B
Woodside JV
McKay GJ
author_sort Browne D
title Vitamin E and Alzheimer’s disease: what do we know so far?
title_short Vitamin E and Alzheimer’s disease: what do we know so far?
title_full Vitamin E and Alzheimer’s disease: what do we know so far?
title_fullStr Vitamin E and Alzheimer’s disease: what do we know so far?
title_full_unstemmed Vitamin E and Alzheimer’s disease: what do we know so far?
title_sort vitamin e and alzheimer’s disease: what do we know so far?
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/b9d2e66d8f634e0ea0e5e80bb9ca25fb
work_keys_str_mv AT browned vitamineandalzheimerrsquosdiseasewhatdoweknowsofar
AT mcguinnessb vitamineandalzheimerrsquosdiseasewhatdoweknowsofar
AT woodsidejv vitamineandalzheimerrsquosdiseasewhatdoweknowsofar
AT mckaygj vitamineandalzheimerrsquosdiseasewhatdoweknowsofar
_version_ 1718399657542942720

Ejemplares similares